Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial

Annals of Internal Medicine

Volumn 139, Issue 4, 2003, Pages

  Abrams, Donald I ^a   Hilton, Joan F ^b   Leiser, Roslyn J ^b   Shade, Starley B ^b   Elbeik, Tarek A ^b   Aweeka, Francesca T ^b   Benowitz, Neal L ^b   Bredt, Barry M ^b   Kosel, Bradley ^b   Aberg, Judith A ^b   Deeks, Steven G ^b   Mitchell, Thomas F ^b   Mulligan, Kathleen ^b   Bacchetti, Peter ^b   McCune, Joseph M ^b   Schambelan, Morris ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CANNABINOID; CANNABIS; CD4 ANTIGEN; CD8 ANTIGEN; DRONABINOL; INDINAVIR; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; VIRUS RNA; TETRAHYDROCANNABINOL;

ADULT; AGED; APPETITE DISORDER; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; T LYMPHOCYTE SUBPOPULATION; UNITED STATES; VIRUS LOAD; WEIGHT GAIN; BLOOD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG INTERACTION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; VIROLOGY;

ADMINISTRATION, ORAL; CANNABINOIDS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; NELFINAVIR; RNA, VIRAL; TETRAHYDROCANNABINOL; VIRAL LOAD;

EID: 0141677644     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-4-200308190-00008     Document Type: Article

References (44)

1. Abel EL. Marijuana: The First Twelve Thousand Years. New York: Plenum Pr; 1980.
2. Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293: 795-7. [PMID: 1099449]
3. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med. 1979;91:819-24. [PMID: 293141]
4. Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al. Delta-9-tetrahydrocannabinol as an antiemeric for patients receiving cancer chemotherapy. A comparison with prochlotperazine and a placebo. Ann Intern Med. 1979;91:825-30. [PMID: 517882]
5. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981;47:1746-51. [PMID: 6261926]
6. Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection [Letter]. AIDS. 1992;6:127. [PMID: 1311935]
7. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97. [PMID: 7730690]
8. Koder DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-7. [PMID: 2773823]
9. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21-43. [PMID: 3012605]
10. Abrams DI, Child CC, Mitchell T. Marijuana, the AIDS wasting syndrome, and the U.S. government [Letter]. N Engl J Med. 1995;333:670-1.
11. Abrams DI. Medical marijuana: tribulations and trials. J Psychoactive Drugs. 1998;30:163-9. [PMID: 9692378]
12. Abrams DI. Potential interventions for HIV/AIDS wasting: an overview. J Acquir Immune Defic Syndr. 2000;25 Suppl 1:S74-80. [PMID: 11126431]
13. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID: 9516219]
14. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1, EuroSIDA Study Group. Lancet. 1998;352:1725-30. [PMID: 9848347]
15. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-6. [PMID: 10605973]
16. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000;30 Suppl 2:S151-9. [PMID: 10860900]
17. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344:984-96. [PMID: 11274626]
18. Child CC, Mitchell TF, Abrams DI. Patterns of therapeutic marijuana use in two community-based cannabis buyers' cooperatives [Abstract]. 12th World AIDS Conference, Geneva, 28 June-3 July 1998. Abstract no. 60569:1105.
19. Braitstein P, Kendall TR, Chan K, Montaner JSG, O'Shaughnessy MV, Hogg RS. Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV+ individuals using medicinal marijuana and antiretrovirals in British Columbia, Canada [Abstract]. XIIIth International AIDS Conference, Durban, South Africa, 9-14 July 2000. Page 326, abstract no. ThPeB5055.
20. Yamamoto I, Watanabe K, Narimatsu S, Yoshimura H. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol. 1995;27:741-6. [PMID: 7584607]
21. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull. 1995;18:1138-41. [PMID: 8535411]
22. Benowitz NL, Jones RT. Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther. 1977;22:259-68. [PMID: 891094]
23. Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther. 1980;28:115-20. [PMID: 7389248]
24. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74:129-80. [PMID: 9336020]
25. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. 1998;38:179-200. [PMID: 9597153]
26. Nahas GG, Suciu-Foca N, Armand JP, Morishima A. Inhibition of cellular mediated immunity in marihuana smokers. Science. 1974;183:419-20. [PMID: 4271816]
27. Friedman H, Klein TW, Newton C, Daaka Y. Marijuana, receptors and immunomodulation. Adv Exp Med Biol. 1995;373:103-13. [PMID: 7668140]
28. Hollister LE. Marijuana and immunity. J Psychoactive Drugs. 1992;24:159-64. [PMID: 1506999]
29. Wallace JM, Tashkin DP, Oishi JS, Barbers RG. Peripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. J Psychoactive Drugs. 1988;20:9-14. [PMID: 3392635]
30. U.S. Public Health Service. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Accessed at http://aidsinfo.nih.gov /guidelines/default_db2.asp?id=50 on 17 February 2003.
31. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288: 222-35. [PMID: 12095387]
32. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433. [PMID: 12617573]
33. Johnson M, Petersen A, Winslade J, Clendennin N. Comparison of BID and TID dosing of VIRACEPT® (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC) [Abstract]. Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1-5 February 1998. Page 148, abstract no. 373.
34. Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988;11:1-14. [PMID: 3228283]
35. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002;16:543-50. [PMID: 11872997]
36. + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929-38. [PMID: 9182469]
37. Paxton WT, Coombs RW, McElrath MJ, Keefer MC, Hughes J, Sinangil F, et al. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1997;175:247-54. [PMID: 9203644]
38. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London: Chapman and Hall; 1993:178-88, 214-8, 398-403.
39. Lesaffre E, Verbeke G. Local influence in linear mixed models. Biometrics. 1998;54:570-82. [PMID: 9629645]
40. Bredt BM, Higuera-Albino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol. 2002;42:82S-89S. [PMID: 12412840]
41. Kane B. Medical marijuana: the continuing story. Ann Intern Med. 2001; 134:1159-62. [PMID: 11412075]
42. Mulligan K, Abrams DI, Leiser RJ, Schambelan M. Body composition changes in HIV-infected men consuming self-selected diets during a placebo-controlled inpatient study of cannabinoids [Abstract]. Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 4-8 February 2001. Page 238, abstract no. 647.
43. Joy JE, Watson SJ, Benson JA, eds. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Pr; 1999.
44. University of California Center for Medicinal Cannabis Research. Accessed at www.cmcr.ucsd.edu on 17 February 2003.